VR Program for Heart Health Education in Breast Cancer Survivors Undergoing Treatment
A study is underway to evaluate VR program aimed at improving heart health knowledge among breast cancer survivors receiving anthracyclines or trastuzumab.
Phase III
breast cancer survivors
Status
Active
Sponsor
pharma companies in oncology
Signal Score
8.2
Signal assessment
Signal strength
high
Confidence level
moderate
Why it matters
This trial represents a significant innovation in supportive care for breast cancer survivors, focusing on cardiac health education through virtual reality. As treatment protocols evolve, integrating such programs could enhance patient outcomes and differentiate offerings in a competitive oncology market.
Recommended action
Humanexa recommends Monitor.
Analysis
Monitor results on usability and effectiveness of the VR program, as well as any changes in patient outcomes related to cardiac health.
Related companies & assets
Companies
Assets
Sources & Humanexa intelligence
Related signals
Newsletter
Get signals before the market moves
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.